Verastem, Inc. (VSTM) Presents Updated Clinical Data From VS-6063 And Paclitaxel Combination Phase 1/1b Study In Patients With Ovarian Cancer At The 2014 American Society of Clinical Oncology Annual Meeting
6/2/2014 10:13:12 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of clinical data in a poster presentation and discussion at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014, at McCormick Place in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by